Craig-Hallum Assumes Avadel Pharmaceuticals (AVDL) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts AVDL Hot Sheet
Price: $21.64 --0%
Rating Summary:
5 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
5 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Craig-Hallum analyst Robin Garner assumes coverage on Avadel Pharmaceuticals (NASDAQ: AVDL) with a Buy rating and a price target of $12.00.
For an analyst ratings summary and ratings history on Avadel Pharmaceuticals click here. For more ratings news on Avadel Pharmaceuticals click here.
Shares of Avadel Pharmaceuticals closed at $4.55 yesterday.
You May Also Be Interested In
- H.C. Wainwright Assumes MiNK Therapeutics (INKT) at Buy
- Guggenheim Starts Lockheed Martin (LMT) at Buy
- Canaccord Starts Carrier Connect Data Solutions (CCDS:CN) at Spec. Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
